White House Pulls Heidi Overton's FDA Nomination as Vaccine, Abortion Pill and Vaping Disputes Fuel Senate Opposition
Summary
The White House withdrew Heidi Overton's nomination to lead the U.S. Food and Drug Administration on November 17, 2026, one day before the Senate Health, Education, Labor and Pensions Committee was scheduled to vote on her confirmation. Overton, a physician and former deputy director of the White House Domestic Policy Council nominated by President Donald Trump in August 2026, faced bipartisan scrutiny over vaccine policy, abortion medication, and flavored nicotine regulation. Senate HELP Committee Chairman Bill Cassidy had questioned her support for the administration's approach to separating certain childhood combination vaccines, while some anti-abortion Republicans demanded additional White House commitments on abortion-related policy. The FDA's May 5 authorization of four Glas Inc. e-liquid pods—including the first non-tobacco, non-menthol e-cigarette flavors (mango-flavored Gold and blueberry-flavored Sapphire)—drew scrutiny from Senator Susan Collins, who raised concerns about youth nicotine use, and Senator Christopher Murphy, who questioned whether political donations influenced the decision. Overton defended the authorizations as following the public-health standard and noted that career FDA reviewers had recommended them. She also faced questions about mifepristone, stating that under current FDA labeling and risk-management requirements the drug was considered safe and effective. Following the withdrawal, Cassidy said he believed Overton could have secured approval, attributing the final disagreement to demands by some anti-abortion Republicans. The FDA remains under acting commissioner Kyle Diamantas, and the White House has not announced a replacement nominee. The agency has experienced significant turnover, with approximately 20% of its workforce departing since Trump returned to office.
(Source:2Firsts)